Our Paris Technology team advised Novo Holdings A/S, Bpifrance, Invus and UI Investissement on their investment in the €32 million Series A financing of Coave Therapeutics, a company pioneering the future of genetic medicines.
The round was co-led by Novo Holdings A/S and Bpifrance, with participation from Invus and UI Investissement, alongside existing investors Seroba Life Sciences, Fund+, Kurma Partners, Omnes Capital and Turenne Capital.
The financing will enable Coave to advance its proprietary ALIGATER™ platform, an innovative technology enhancing genetic delivery to extra-hepatic tissues with improved efficiency, specificity, and safety. It will also advance Coave's preclinical assets toward clinical development, focusing on central nervous system, neuromuscular, and eye diseases, with two candidates planned for clinical trials in 2026.
The Goodwin team was led by Anne-Charlotte Rivière and included Julie Messerig and Grégoire Mongis on corporate aspects and Marie Fillon and Louis de Chezelles on IP aspects.